Tolvaptan-containing pharmaceutical composition as well as preparation method and application thereof

Tovaptan drug was solved by using a composition of torvaptan with mannitol, prulanose, xanthan gum, polysorbate-80 and sucralose combined with shear, degassing and lyophilization treatment. The transformation and molding problems of the composition during the preparation process have achieved stable tablet preparation and disintegration effects, and are suitable for industrial production.

CN118924763APending Publication Date: 2024-11-12BEIJING QUANTUM HI TECH PHARMA TECHCO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310535058.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, tovaptan pharmaceutical compositions are prone to transcrystallization during the preparation process, and are difficult to have both good molding and rapid disintegration, resulting in poor drug quality and safety hazards and complex process problems in industrial production.

Method used

Preparation by mixing, shearing, degassing, prefrost and lyophilization treatment using pharmaceutical compositions containing torvaptan, mannitol, prulanose, xanthan gum, polysorbate-80 and sucralose Methods, stable tablets are formed to ensure the moldability and disintegration of the pharmaceutical composition.

Benefits of technology

It effectively avoids the crystallization phenomenon, improves the stability and moldability of the pharmaceutical composition, ensures the rapid and uniform disintegration of the tablet, simplifies the preparation process, reduces safety risks, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924763A_ABST
    Figure CN118924763A_ABST
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition containing tolvaptan and a preparation method and application thereof.The pharmaceutical composition comprises effective dosages of tolvaptan, a skeleton supporting agent, an adhesive, a suspending aid, a surfactant and a flavoring agent, the skeleton supporting agent is mannitol, the adhesive is pullulan, the suspending aid is sodium dodecyl sulfate, the surfactant is sodium dodecyl sulfate, and the flavoring agent is sodium dodecyl sulfate. The suspending aid is xanthan gum, the surfactant is polysorbate-80, and the flavoring agent is sucralose. According to the invention, a preparation formula and a preparation process of the pharmaceutical composition containing tolvaptan are improved. The preparation formula provided by the invention effectively improves the problems of unstable intermediate liquid medicine and non-uniform preparation caused by different particle sizes of raw material medicines, ensures that no crystal transformation phenomenon occurs in the preparation process, and ensures that the tablets have better formability and excellent stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceuticals, and in particular to a pharmaceutical composition containing tolvaptan, and a preparation method and application thereof. Background Art

[0002] Tolvaptan, developed by Otsuka Pharmaceutical, is for the treatment of clinically significant hypervolemic and normovolemic hyponatremia (serum sodium concentration <125 mEq / L, or subtle but symptomatic hyponatremia that is refractory to fluid restriction), including patients with heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

[0003] Tolvaptan is a vasopressin V2 receptor antagonist. After oral administration, it antagonizes AVP (natural arginine vasopressin, also known as antidiuretic hormone), improves the clearance of free water, and then increases the serum sodium concentration to treat hyponatremia. Because it can act as a diuretic and excrete body fluids, it is also used to treat fluid retention. The main manifestation of heart failure is fluid retention, and another indication for tolvaptan is fluid retention caused by heart failure. At the 32nd Great Wall Cardiology Conference (GW-ICC2021), cardiologists pointed out that when patients with heart failure reduce myocardial congestion, they must first limit salt and water. In addition to the commonly used "old three", namely loop diuretics, thiazide diuretics, and potassium-sparing diuretics, "new four" have been added, including vasopressin V2 receptor antagonists, recombinant human brain natriuretic peptide, SGLT-2 inhibitors, and traditional Chinese medicine. Tolvaptan is one of the "new four".

[0004] Patent document CN102470178B discloses a tolvaptan solid dispersion and a preparation method thereof, wherein amorphous active ingredient tolvaptan or its salt and cross-linked polyvinyl pyrrolidone are prepared as a solid dispersion. The active ingredient is first dissolved in an organic solvent, cross-linked polyvinyl pyrrolidone and a water-soluble polymer are dissolved or dispersed in the organic solvent, and then evaporation, spray drying or fluidized bed drying are adopted. Organic solvents include: methanol, ethanol, isopropanol, acetone, butanone, dichloromethane, dichloroethane, chloroform or carbon tetrachloride. The process is complicated. If spray drying or fluidized bed drying is adopted, organic solvents will bring potential safety hazards, and industrial large-scale production is not easy to achieve.

[0005] Patent document CN107982268A discloses a tolvaptan preparation and its application, which is prepared from tolvaptan, lactose, microcrystalline cellulose and a pharmaceutically acceptable carrier. Among them, the tablet of tolvaptan can be prepared according to the following method, firstly, tolvaptan is deposited on the surface of the carrier matrix to prepare the composition. This step is completed by the following operations: forming a solution of tolvaptan and an adhesive substance, and then applying the solution in a spraying manner while the carrier matrix particles are kept moving. Then the dried particles are mixed with a disintegrant / glidant / lubricant, and finally the obtained powder is pressed into tablets. The process preparation process is cumbersome, and it cannot be guaranteed that crystal transformation will not occur during the preparation process, and the obtained tablets cannot have the characteristics of good molding and rapid disintegration.

[0006] The pharmaceutical composition containing tolvaptan prepared by the existing prescription or preparation method cannot overcome the problem of poor drug quality caused by crystal transformation of the raw materials during the preparation process. On this basis, it cannot ensure that the prepared tablets have the characteristics of good molding and rapid disintegration. Summary of the invention

[0007] The present invention overcomes the defects in the prior art and provides a pharmaceutical composition containing tolvaptan and a preparation method and application thereof.

[0008] The first aspect of the present invention provides a pharmaceutical composition containing tolvaptan, wherein the pharmaceutical composition comprises an effective dose of tolvaptan, a skeleton support agent, a binder, a suspending agent, a surfactant and a flavoring agent, wherein the skeleton support agent is mannitol, the binder is pullulan, the suspending agent is xanthan gum, the surfactant is polysorbate-80, and the flavoring agent is sucralose.

[0009] Further, the pharmaceutical composition contains 0.5-10 parts of tolvaptan by weight (such as 0.5 parts, 1 parts, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.1 parts, 3.2 parts, 3.3 parts, 3.4 parts, 3.5 parts, 3.6 parts, 3.7 parts, 3.8 parts, 3.9 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts), preferably, the pharmaceutical composition contains 1-8 parts of tolvaptan by weight, further preferably, the pharmaceutical composition contains 1-5 parts of tolvaptan by weight, further preferably, the pharmaceutical composition contains 1-4 parts of tolvaptan by weight, and particularly preferably, the pharmaceutical composition contains 2-4 parts of tolvaptan by weight.

[0010] In one embodiment of the present invention, the pharmaceutical composition contains 3.75 parts of tolvaptan by weight.

[0011] Furthermore, the pharmaceutical composition contains 0.5-10 parts of mannitol by weight (such as 0.5 parts, 1 parts, 1.5 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, 2.6 parts, 2.7 parts, 2.8 parts, 2.9 parts, 3 parts, 3.1 parts, 3.2 parts, 3.3 parts, 3.4 parts, 3.5 parts, 3.6 parts, 3.7 parts, 3.8 parts, 3.9 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts). Preferably, the pharmaceutical composition contains 1-8 parts of mannitol by weight, further preferably, the pharmaceutical composition contains 1-5 parts of mannitol by weight, even further preferably, the pharmaceutical composition contains 1-4 parts of mannitol by weight, particularly preferably, the pharmaceutical composition contains 2-4 parts of mannitol by weight.

[0012] In one embodiment of the present invention, the pharmaceutical composition contains 3 parts of mannitol by weight.

[0013] Further, the pharmaceutical composition contains 0.1-10 parts of pullulan by weight (such as 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 1 parts, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, 2.6 parts, 2.7 parts, 2.8 parts, 2.9 parts, 3 parts, 3.1 parts, 3.2 parts, 3.3 parts, 3.4 parts, 3.5 parts, 3.6 parts, 3.7 parts, 3.8 parts, 3.9 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts), preferably, the pharmaceutical composition contains 0.1-8 parts of pullulan by weight, further preferably, the pharmaceutical composition contains 0.1-5 parts of pullulan by weight, further preferably, the pharmaceutical composition contains 0.1-4 parts of pullulan by weight, particularly preferably, the pharmaceutical composition contains 0.5-4 parts of pullulan by weight.

[0014] In one embodiment of the present invention, the pharmaceutical composition contains 1.5 parts of pullulan by weight.

[0015] Furthermore, the pharmaceutical composition contains 0.01-5 parts of xanthan gum by weight (such as 0.01 parts, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.11 parts, 0.12 parts, 0.13 parts, 0.14 parts, 0.15 parts, 0.2 parts, 0.25 parts, 0.3 parts, 0.35 parts, 0.4 parts, 0.45 parts, 0.5 parts, 0.55 parts, 0.6 parts, 0.65 parts, 0.7 parts, 0.75 parts, 0.8 parts, 0.85 parts, 0.9 Preferably, the pharmaceutical composition contains 0.01-4 parts of xanthan gum by weight, further preferably, the pharmaceutical composition contains 0.01-3 parts of xanthan gum by weight, even further preferably, the pharmaceutical composition contains 0.05-3 parts of xanthan gum by weight, particularly preferably, the pharmaceutical composition contains 0.05-2 parts of xanthan gum by weight.

[0016] In one embodiment of the present invention, the pharmaceutical composition contains 0.1 parts of xanthan gum by weight.

[0017] Furthermore, the pharmaceutical composition contains 0.001-5 parts of polysorbate-80 by weight (e.g., 0.001 parts, 0.005 parts, 0.01 parts, 0.015 parts, 0.02 parts, 0.025 parts, 0.03 parts, 0.035 parts, 0.04 parts, 0.045 parts, 0.05 parts, 0.055 parts, 0.06 parts, 0.065 parts, 0.07 parts, 0.071 parts, 0.072 parts, 0.073 parts, 0.074 parts, 0.075 parts, 0.076 parts, 0.0 78 parts, 0.079 parts, 0.08 parts, 0.085 parts, 0.09 parts, 0.095 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1.0 parts, 1.5 parts, 2.0 parts, 2.5 parts, 3.0 parts, 3.5 parts, 4.0 parts, 4.5 parts, 5.0 parts), preferably, the pharmaceutical composition contains 0.001-3 parts of polysorbate 80 by weight, further preferably, the pharmaceutical composition contains 0.001-2 parts of polysorbate 80 by weight, further preferably, the pharmaceutical composition contains 0.05-2 parts of polysorbate 80 by weight, particularly preferably, the pharmaceutical composition contains 0.05-1 parts of polysorbate 80 by weight.

[0018] In one embodiment of the present invention, the pharmaceutical composition contains 0.075 parts of polysorbate-80 by weight.

[0019] Furthermore, the pharmaceutical composition contains 0.01-5 parts of sucralose by weight (e.g., 0.01 parts, 0.05 parts, 0.06 parts, 0.07 parts, 0.08 parts, 0.09 parts, 0.1 parts, 0.11 parts, 0.12 parts, 0.13 parts, 0.14 parts, 0.15 parts, 0.2 parts, 0.25 parts, 0.3 parts, 0.35 parts, 0.4 parts, 0.45 parts, 0.5 parts, 0.55 parts, 0.6 parts, 0.65 parts, 0.7 parts, 0.75 parts, 0.8 parts, 0.85 parts, 0.9 parts) , 0.95 parts, 1.0 parts, 1.5 parts, 2.0 parts, 2.5 parts, 3.0 parts, 3.5 parts, 4.0 parts, 4.5 parts, 5.0 parts), preferably, the pharmaceutical composition contains 0.01-4 parts of sucralose by weight, further preferably, the pharmaceutical composition contains 0.01-3 parts of sucralose by weight, further preferably, the pharmaceutical composition contains 0.05-3 parts of sucralose by weight, particularly preferably, the pharmaceutical composition contains 0.05-2 parts of sucralose by weight.

[0020] In one embodiment of the present invention, the pharmaceutical composition contains 0.1 parts of sucralose by weight.

[0021] In one embodiment of the present invention, the pharmaceutical composition comprises:

[0022] Tolvaptan 0.5-10 parts,

[0023] Mannitol 0.5-10 parts,

[0024] Pullulan 0.1-10 parts,

[0025] Xanthan gum 0.01-5 parts,

[0026] Polysorbate-80 0.001-5 parts and

[0027] Sucralose 0.01-5 parts.

[0028] In one embodiment of the present invention, the pharmaceutical composition comprises:

[0029] Tolvaptan 2-4 parts,

[0030] 2-4 parts of mannitol,

[0031] 0.5-4 parts of pullulan,

[0032] Xanthan gum 0.05-2 parts,

[0033] Polysorbate-80 0.05-1 parts and

[0034] Sucralose 0.05-2 parts.

[0035] In one embodiment of the present invention, the pharmaceutical composition comprises:

[0036] Tolvaptan 3.75 parts,

[0037] 3 parts of mannitol,

[0038] 1.5 parts of pullulan,

[0039] 0.1 part xanthan gum,

[0040] Polysorbate-80 0.075 parts and

[0041] Sucralose 0.1 parts.

[0042] The second aspect of the present invention provides a method for preparing the above-mentioned pharmaceutical composition, which comprises the following steps:

[0043] (1) Mix mannitol, pullulan, xanthan gum, polysorbate 80 and sucralose and add water;

[0044] (2) adding tolvaptan to the mixed material obtained in step (1) and adding water;

[0045] (3) subjecting the mixed material obtained in step (2) to shearing treatment;

[0046] (4) degassing the mixed material obtained in step (3);

[0047] (5) injecting the mixed material obtained in step (4) into a mold;

[0048] (6) pre-freezing the mold filled with the mixed material in step (5);

[0049] (7) freeze-drying the mold filled with the mixed material after the pre-freezing treatment in step (6).

[0050] Furthermore, the rotation speed of the shearing treatment in step (3) is 1000-5000 rpm (such as 1000 rpm, 1500 rpm, 2000 rpm, 2500 rpm, 3000 rpm, 3500 rpm, 4000 rpm, 4500 rpm, 5000 rpm), preferably, 1000-3000 rpm.

[0051] In a specific embodiment of the present invention, the rotation speed of the shearing treatment in step (3) is 2500 rpm.

[0052] Furthermore, the time of the shear treatment in step (3) is 1-20 min (such as 1 min, 2 min, 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min, 10 min, 11 min, 12 min, 13 min, 14 min, 15 min, 16 min, 17 min, 18 min, 19 min, 20 min), preferably, 1-10 min.

[0053] In a specific embodiment of the present invention, the shearing treatment time in step (3) is 5 minutes.

[0054] Furthermore, the injection volume in step (5) is 330 μL or 165 μL.

[0055] Furthermore, the temperature of the pre-freezing treatment in step (6) is -40°C to -80°C (such as -40°C, -45°C, -50°C, -55°C, -60°C, -65°C, -70°C, -75°C, -80°C), preferably, -50°C to -70°C.

[0056] In a specific embodiment of the present invention, the temperature of the pre-freezing treatment in step (6) is -60°C.

[0057] Furthermore, the freeze-drying process in step (7) includes:

[0058] Set the initial temperature to -30℃;

[0059] Set the cold trap temperature: -40℃~-70℃, vacuum degree 20pa~30pa;

[0060] The freeze-drying curve is as follows:

[0061] From -30℃ to -15℃, 15min;

[0062] Maintain at -15°C for 120 min;

[0063] From -15℃ to -1℃, 14min;

[0064] Maintain at -1°C for 60 min;

[0065] From -1℃ to 25℃, 26min;

[0066] Maintain at 25°C for 60 min.

[0067] The third aspect of the present invention provides a use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating soluble or hypervolemic hyponatremia.

[0068] The present invention improves the formulation and preparation process of a pharmaceutical composition containing tolvaptan. The formulation of the present invention effectively improves the problems of instability of the intermediate drug solution and uneven preparation caused by different particle sizes of the raw materials, and at the same time ensures that no crystal transformation occurs during the preparation process, thereby ensuring that the tablet has good formability and excellent stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 It is a top view of the orodisintegrating tablet preparation.

[0070] Figure 2 It is a side view of an orally disintegrating tablet formulation.

[0071] Figure 3 This is a cross section of an orally disintegrating tablet.

[0072] Figure 4 This is a diagram of the disintegration state of orodisintegrating tablets. DETAILED DESCRIPTION

[0073] In order to more clearly understand the technical content of the present invention, the following embodiments are given in detail, the purpose of which is only to better understand the content of the present invention but not to limit the protection scope of the present invention.

[0074] Example 1

[0075] prescription

[0076] name Prescription quantity / tablet (theoretical) Prescription quantity / tablet (actual) Specification 165μL / tablet or 330μL / tablet 165μL / tablet or 330μL / tablet Tolvaptan 3.75g 3.75g Mannitol 3g 3g Pullulan 1.5g 1.5g Xanthan gum 100mg 100.3mg Polysorbate-80 0.075g 0.08g Sucralose 100mg 100.7mg Purified water 79.075g 78.969g Total weight 87.5g 87.5g

[0077] Preparation process

[0078] (1) Weigh the empty beaker (200 mL) and the glass rod to a total weight of 87.63 g;

[0079] (2) Weigh the prescribed amount of mannitol, pullulan, xanthan gum, polysorbate 80, and sucralose into a 200 mL beaker, dry mix, add an appropriate amount (about 80 scale) of purified water, and mix to dissolve;

[0080] After adding the prescribed amount of tolvaptan, add purified water to make the volume to 175.13 g and mix well to completely wet the API;

[0081] (3) Shearing: speed 2500 rpm, time 5 min, observe the state of the solution after shearing;

[0082] (4) Degassing: Transfer the solution to a 250 mL degassing bottle and evacuate until no bubbles are generated;

[0083] (5) Sample injection and pre-freezing: Use a pipette to inject the sample, the injection volume is 330μL / tablet (160 tablets) or 165μL / tablet (120 tablets). Place the injected aluminum-plastic blister in a -60℃ low-temperature storage box and pre-freeze until freeze-dried;

[0084] (6) Freeze drying: Set the initial temperature of the freeze dryer to -30°C, and place the pre-frozen sample into the freeze drying box after cooling. The specific freeze drying parameters are as follows:

[0085] Cold trap temperature: -40℃~-70℃, vacuum degree 20pa~30pa;

[0086] The freeze-drying curve is as follows:

[0087] From -30℃ to -15℃, 15min;

[0088] Maintain at -15°C for 120 min;

[0089] From -15℃ to -1℃, 14min;

[0090] Maintain at -1°C for 60 min;

[0091] From -1℃ to 25℃, 26min;

[0092] Maintain at 25°C for 60 min.

[0093] Out of the box.

[0094] (7) After freeze-drying, remove the sample, conduct a preliminary inspection of the freeze-dried sheet, and cover the remaining sample with film.

[0095] Example 2

[0096]

[0097]

[0098]

[0099] Appearance: The tablets are complete and full, white freeze-dried tablets.

[0100] Disintegration: 5+ (good)

[0101] After lamination, the samples were not pressed.

[0102] Conclusion: Reducing the particle size of the API can improve the state of the intermediate solution and has little effect on the appearance of the finished freeze-dried tablets.

Claims

1. A pharmaceutical composition containing tolvaptan, characterized in that: The pharmaceutical composition comprises an effective dose of tolvaptan, a skeleton support agent, a binder, a suspending agent, a surfactant and a flavoring agent, wherein the skeleton support agent is mannitol, the binder is pullulan, the suspending agent is xanthan gum, the surfactant is polysorbate-80, and the flavoring agent is sucralose.

2. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition contains 0.5-10 parts of tolvaptan by weight, preferably, the pharmaceutical composition contains 1-8 parts of tolvaptan by weight, further preferably, the pharmaceutical composition contains 1-5 parts of tolvaptan by weight, further preferably, the pharmaceutical composition contains 1-4 parts of tolvaptan by weight, and particularly preferably, the pharmaceutical composition contains 2-4 parts of tolvaptan by weight.

3. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition contains 0.5-10 parts of mannitol by weight, preferably, the pharmaceutical composition contains 1-8 parts of mannitol by weight, further preferably, the pharmaceutical composition contains 1-5 parts of mannitol by weight, further preferably, the pharmaceutical composition contains 1-4 parts of mannitol by weight, and particularly preferably, the pharmaceutical composition contains 2-4 parts of mannitol by weight.

4. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition contains 0.1-10 parts of pullulan by weight, preferably, the pharmaceutical composition contains 0.1-8 parts of pullulan by weight, further preferably, the pharmaceutical composition contains 0.1-5 parts of pullulan by weight, further preferably, the pharmaceutical composition contains 0.1-4 parts of pullulan by weight, and particularly preferably, the pharmaceutical composition contains 0.5-4 parts of pullulan by weight.

5. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition contains 0.01-5 parts of xanthan gum by weight, preferably, the pharmaceutical composition contains 0.01-4 parts of xanthan gum by weight, further preferably, the pharmaceutical composition contains 0.01-3 parts of xanthan gum by weight, further preferably, the pharmaceutical composition contains 0.05-3 parts of xanthan gum by weight, and particularly preferably, the pharmaceutical composition contains 0.05-2 parts of xanthan gum by weight.

6. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition contains 0.001-5 parts of polysorbate 80 by weight, preferably, the pharmaceutical composition contains 0.001-3 parts of polysorbate 80 by weight, further preferably, the pharmaceutical composition contains 0.001-2 parts of polysorbate 80 by weight, further preferably, the pharmaceutical composition contains 0.05-2 parts of polysorbate 80 by weight, and particularly preferably, the pharmaceutical composition contains 0.05-1 parts of polysorbate 80 by weight.

7. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition contains 0.01-5 parts of sucralose by weight, preferably, the pharmaceutical composition contains 0.01-4 parts of sucralose by weight, further preferably, the pharmaceutical composition contains 0.01-3 parts of sucralose by weight, further preferably, the pharmaceutical composition contains 0.05-3 parts of sucralose by weight, and particularly preferably, the pharmaceutical composition contains 0.05-2 parts of sucralose by weight.

8. The method for preparing the pharmaceutical composition according to claim 1, comprising the steps of: (1) Mix mannitol, pullulan, xanthan gum, polysorbate 80 and sucralose and add water; (2) adding tolvaptan to the mixed material obtained in step (1) and adding water; (3) subjecting the mixed material obtained in step (2) to shearing treatment; (4) degassing the mixed material obtained in step (3); (5) injecting the mixed material obtained in step (4) into a mold; (6) pre-freezing the mold filled with the mixed material in step (5); (7) freeze-drying the mold filled with the mixed material after the pre-freezing treatment in step (6).

9. The preparation method according to claim 8, characterized in that: The freeze-drying process described in step (7) includes: Set the initial temperature to -30℃; Set the cold trap temperature: -40℃~-70℃, vacuum degree 20pa~30pa; The freeze-drying curve is as follows: From -30℃ to -15℃, 15min; Maintain at -15°C for 120 min; From -15℃ to -1℃, 14min; Maintain at -1°C for 60 min; From -1℃ to 25℃, 26min; Maintain at 25°C for 60 min.

10. Use of the pharmaceutical composition according to claim 1 in the preparation of a drug for treating volumetric or hypervolumetric hyponatremia.